CDRH has developed a novel risk-based strategy for designing pivotal trials for weight-loss devices, with plans to set the effectiveness endpoints based on adverse event rates observed in feasibility studies.
FDA Proposes Sliding-Scale Paradigm For Obesity Device Trials
Higher-risk devices, based on feasibility trial adverse event rates, would be matched to steeper effectiveness targets in pivotal studies for weight-loss under a plan outlined by the agency.